Allergy Therapeutics plc has disclosed a public dealing disclosure by an exempt principal trader, Panmure Gordon (UK) Limited, in accordance with Rule 8.5 of the Takeover Code. The disclosure relates to dealings in the securities of Allergy Therapeutics plc on 20 September 2023. The exempt principal trader made purchases and sales of the 0.1p ordinary shares of Allergy Therapeutics plc. The highest price per unit paid for the purchases was 0.026p, while the lowest price per unit paid was 0.0242p. The highest price per unit received for the sales was 0.02698p, and the lowest price per unit received was 0.0258p.

No cash-settled derivative transactions or stock-settled derivative transactions were disclosed in relation to Allergy Therapeutics plc.

The disclosure does not include any indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. There are also no agreements, arrangements, or understandings relating to options or derivatives.

The disclosure was made on 21 September 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.

This disclosure is in compliance with the Code's dealing disclosure requirements, and public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.